UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2010
ALIMERA SCIENCES, INC.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| |
|
|
|
001-34703
(Commission File No.)
|
|
20-0028718
(IRS Employer Identification No.) |
6120 Windward Parkway
Suite 290
Alpharetta, Georgia 30005
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (678) 990-5740
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On August 12, 2010, Alimera Sciences, Inc. (the “Company”) issued a press release and is
holding a conference call regarding its results of operations and financial condition for the
second quarter ended June 30, 2010. The full text of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K.
Various statements to be made during the conference call are “forward-looking statements,”
within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other
things, the Company’s future results of operations and financial position, business strategy and
plans and objectives of management for the Company’s future operations. Words such as
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,”
“likely,” “will,” “would,” “could,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying
words. The events and circumstances reflected in the Company’s forward-looking statements may not
occur and actual results could differ materially from those projected in the Company’s
forward-looking statements. Meaningful factors which could cause actual results to differ include,
but are not limited to, delay in or failure to obtain regulatory approval of the Company’s product
candidates, uncertainty as to the Company’s ability to commercialize, and market acceptance of, the
Company’s product candidates, the extent of government regulations, uncertainty as to the
relationship between the benefits of the Company’s product candidates and the risks of their
side-effect profiles, dependence on third-party manufacturers to manufacture the Company’s product
candidates in sufficient quantities and quality, uncertainty of clinical trial results, limited
sales and marketing infrastructure, as well as other factors discussed in the Company’s Securities
and Exchange Commission filings, including the Company’s quarterly report on Form 10-Q for the
fiscal quarter ended March 31, 2010, which was filed with the Securities and Exchange Commission on
June 7, 2010. Additional information will also be set forth in the Company’s quarterly report on
Form 10-Q for the fiscal quarter ended June 30, 2010, which will be filed with the Securities and
Exchange Commission in the third quarter of 2010.
All forward-looking statements made during the conference call are expressly qualified by the
above paragraph in their entirety. These forward-looking statements speak only as of the date of
the conference call (unless another date is indicated). The Company undertakes no obligation, and
specifically declines any obligation, to publicly update or revise any forward-looking statements
which are made during the conference call, whether as a result of new information, future events or
otherwise.
The information in Item 2.02 of this Current Report on Form 8-K and the press release attached
hereto as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.